All News

According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.

W. Kimryn Rathmell, MD, PhD, an internationally recognized expert in kidney cancer, is Chair of the Department of Medicine and Physician-in-Chief at Vanderbilt University Medical Center.

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain.

Further, men with Peyronie disease treated with PRP injections demonstrated a 25% reduction in curvature at a median of 10 degrees after 6 months.

At 5 years from CCH injection, curvature and plaque volume were associated with patient satisfaction in the treatment of their Peyronie’s disease.

Severe SUI was defined as 3 or more pads daily and severe erectile dysfunction was defined as an International Index of Erectile Function score of 10 or lower.

Findings showing an increased risk for UTIs highlight the importance of follow-up and counseling of women during the initiation of anti-androgen therapy.

In a retrospective study of almost 500 men, the use of hyaluronic acid filler for penile girth enhancement appeared safe with limited adverse events.

At baseline, 16 patients had an IIEF-EF score of 11-21. These patients reported significant improvement in IIEF-EF score at Times 2 and 4, according to the authors.

Compared with retail and Medicare pricing, the use of discount listings can induce significant cost savings, improving patient adherence to vaginal estrogen treatment.

At 4 years post-surgery, men receiving Rezum had preserved and/or improved sexual function and better lower urinary tract symptoms secondary to benign prostatic hyperplasia.

The FDA has approved enzalutamide for use with or without a GnRH analog therapy for the treatment of patients with nonmetastatic castration-sensitive prostate cancer.

Although traditional payment and communication methods remain relevant, the survey highlights a paradigm shift in patients' billing expectations overall.

Data from the phase 2 LITESPARK-004 trial led to the FDA approval of belzutifan for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma and other diseases.

"This is the 15th year [of LUGPA,] and I think I've gone maybe 12, 13 years in a row or so, almost every year," says Lawrence Gervasi, MD.

The novel TKI zanzalintinib demonstrated early efficacy signals with manageable toxicity in patients with advanced clear-cell renal cell carcinoma.

“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.

"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.

Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.

The ProstACT GLOBAL study is investigating second-line TLX591 in combination with the current standard of care (SOC) vs SOC alone in patients with mCRPC who have progressed on a novel androgen axis drug.

Circulating tumor DNA is showing promise as a tool to guide decisions on treatment intensification and de-escalation in patients with renal cell carcinoma.

Translocation renal cell carcinoma is a rare type of RCC that is typically characterized by gene fusions involving the MiT family of transcription factors including TFE3, TFEB, TFEC, and MiTF.

Notably, the study represents a 57% increase in the number of non-European participants compared with previous prostate cancer genome-wide association studies.

"Keeping up-to-date is challenging, and rapid progress that is now occurring in our field is truly amazing," writes Michael S. Cookson, MD, MMHC, FACS.

“This study confirms what many women who’ve struggled with persistent UTIs already know, which is that the current methods of diagnosing and treating these infections are inadequate," says Jennifer Rohn, PhD.

The CPT code will be effective beginning July 1, 2024.

Researchers utilized the PI-QUAL scoring system to assess 355 mpMRI exams performed at 41 facilities in 18 countries.

"The end of the year presents a good opportunity to regroup, close out 2023 in the strongest position possible, and ready yourself for 2024," writes Jeff Witz, CFP.